Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study

Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study

The purpose of this pilot study is to examine changes in patient-reported outcomes in patients with RRMM receiving triple therapy with ixazomib in combination with LenDex in a real world setting as well as to analyze clinical outcomes and safety of this treatment modality.

Inclusion Criteria:

• Adult patients with confirmed diagnosis of RRMM
• At least 18 years of age at the time of treatment start
• Patients who have received at least one prior therapy and who are suitable for treatment with ixazomib in combination with LenDex
• Patients who gave informed consent
• Patients who are capable to fill out questionnaires
• Patients with expected life duration of at least 6 months

Exclusion Criteria:

• Patients currently enrolled in any other clinical trials
• Patients with contraindications to ixazomib in accordance with instruction for use.